BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $149.27M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.37M
Average 0.37M
Dividends
BridgeBio Oncology Therapeutics Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does BridgeBio Oncology Therapeutics Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Kodiak Sciences Inc. NASDAQ:KOD | $6.99B | 0.00% | $0.00 | 0.00% | 0.00% |
Tango Therapeutics, Inc. NASDAQ:TNGX | $4.32B | 0.00% | $0.00 | 0.00% | 0.00% |
Xencor, Inc. NASDAQ:XNCR | $2.78B | 0.00% | $0.00 | 0.00% | 0.00% |
Septerna Inc NASDAQ:SEPN | $2.03B | 0.00% | $0.00 | 0.00% | 0.00% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | 0.00% | $0.00 | 0.00% | 0.00% |
AnaptysBio, Inc. NASDAQ:ANAB | $1.38B | 0.00% | $0.00 | 0.00% | 4.56% |
UroGen Pharma Ltd. NASDAQ:URGN | $1.28B | 0.00% | $0.00 | 0.00% | 0.00% |
Phathom Pharmaceuticals, Inc. NASDAQ:PHAT | $492.63M | 0.00% | $0.00 | 0.00% | 0.00% |
Oculis Holding AG NASDAQ:OCS | $471.63M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about BBOT's dividend, answered from reported figures.
Does BBOT stock pay dividends?
BridgeBio Oncology Therapeutics Inc. (BBOT) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is BBOT's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.